Eli Lilly and Company $LLY Shares Purchased by Triglav Investments D.O.O.

Triglav Investments D.O.O. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 54,036 shares of the company’s stock after buying an additional 791 shares during the period. Eli Lilly and Company makes up about 3.0% of Triglav Investments D.O.O.’s investment portfolio, making the stock its 9th largest position. Triglav Investments D.O.O.’s holdings in Eli Lilly and Company were worth $42,121,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of LLY. PNC Financial Services Group Inc. boosted its position in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Assenagon Asset Management S.A. grew its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after acquiring an additional 765,010 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson bought 200 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $862.96 on Friday. The company has a market cap of $816.76 billion, a PE ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47. The business’s 50 day moving average is $780.74 and its two-hundred day moving average is $771.71. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. JPMorgan Chase & Co. lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.